WO2009126211A3 - Controlled release formulation of water insoluble drug and methods of preparation and treatment - Google Patents

Controlled release formulation of water insoluble drug and methods of preparation and treatment Download PDF

Info

Publication number
WO2009126211A3
WO2009126211A3 PCT/US2009/001931 US2009001931W WO2009126211A3 WO 2009126211 A3 WO2009126211 A3 WO 2009126211A3 US 2009001931 W US2009001931 W US 2009001931W WO 2009126211 A3 WO2009126211 A3 WO 2009126211A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
preparation
methods
controlled release
water insoluble
Prior art date
Application number
PCT/US2009/001931
Other languages
French (fr)
Other versions
WO2009126211A2 (en
Inventor
Michael Campbell
Jack F. Youngren
Ira Goldfine
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2009126211A2 publication Critical patent/WO2009126211A2/en
Publication of WO2009126211A3 publication Critical patent/WO2009126211A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

An implant for use in method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydrogluaiaretic acid (NDGA) and doxyrubicine.
PCT/US2009/001931 2008-04-07 2009-03-25 Controlled release formulation of water insoluble drug and methods of preparation and treatment WO2009126211A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4303208P 2008-04-07 2008-04-07
US61/043,032 2008-04-07

Publications (2)

Publication Number Publication Date
WO2009126211A2 WO2009126211A2 (en) 2009-10-15
WO2009126211A3 true WO2009126211A3 (en) 2009-12-30

Family

ID=41162431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/001931 WO2009126211A2 (en) 2008-04-07 2009-03-25 Controlled release formulation of water insoluble drug and methods of preparation and treatment

Country Status (1)

Country Link
WO (1) WO2009126211A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653992A (en) * 1993-07-20 1997-08-05 Ethicon, Inc. Liquid absorbable copolymers for parenteral applications
US5823993A (en) * 1994-02-18 1998-10-20 Lemelson; Jerome H. Computer controlled drug injection system and method
US20060141025A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653992A (en) * 1993-07-20 1997-08-05 Ethicon, Inc. Liquid absorbable copolymers for parenteral applications
US5823993A (en) * 1994-02-18 1998-10-20 Lemelson; Jerome H. Computer controlled drug injection system and method
US20060141025A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases

Also Published As

Publication number Publication date
WO2009126211A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
MX2010010300A (en) Mtor inhibitor salt forms.
WO2012091956A3 (en) Continuous indentation lateral lobe apparatus and method
WO2012030593A3 (en) Methods and compositions for delivering interleukin-1 receptor antagonist
WO2011026966A3 (en) Method of treating eosinophilic esophagitis
EA200800726A1 (en) INTRODUCTION OF DIPEPTIDYLPEPTIDASE INHIBITORS
PT2073811E (en) Kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
NZ590258A (en) Kinase inhibitors and methods of use
IL211952A0 (en) Implantable device for the delivery of risperidone and methods of use thereof
GB2444593B (en) Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
PT2349260E (en) Janus kinase inhibitors for treatment of dry eye and other eye related diseases
WO2012068162A3 (en) Vascular treatment device
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
AU2008320633A8 (en) Method for reducing the water penetration over time during use in an item of footwear
MX2010002005A (en) 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors.
WO2011123719A3 (en) Use of faah inhibitors for treating abdominal, visceral and pelvic pain
MX336209B (en) Delivery of dry formulations of octreotide.
MX2009008166A (en) Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts.
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
MY182793A (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2009103067A3 (en) Compositions and methods to treat asthma
EA200970851A1 (en) WEEKLY INTRODUCTION OF DIPEPTIDYLPEPIDASE INHIBITORS
ZA201102949B (en) Implantable device for the delivery of octreotide and methods of use thereof
NZ592049A (en) Compositions and methods for the treatment of bowel diseases with granulated mesalamine
EP2249823A4 (en) Octanoic acid formulations and methods of treatment using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729684

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09729684

Country of ref document: EP

Kind code of ref document: A2